We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.50 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 20.25
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 2018 Market Update

18 Apr 2018 07:00

RNS Number : 2307L
Iofina PLC
18 April 2018
 

 

18 April 2018

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Q1 2018 Market Update

Production at Iofina's New IOsorb® Plant Ramps Up

 

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, today provides an update to the market regarding its activities in the first quarter ("Q1" or the "Period") of 2018, during which the new IO#7 plant began production of iodine.

 

In the Period Iofina produced 118.2 metric tonnes ("MT") of crystalline iodine from its operating Oklahoma based IOsorb® plants, which was in line with Q1 last year (2017: 118.7MT), when five plants were operating. Operations in January and February were impacted by extreme winter weather in Oklahoma and a greater diversion of brine flow, including at IO#5, than had been anticipated. Despite these headwinds, the Company achieved a similar Q1 output compared with the previous year despite not operating IOsorb® plants IO#3 and IO#5, demonstrating improved production efficiencies. Iodine production run-rate for the Group in March was significantly higher than in the first two months of the year.

 

During the Period, Iofina opened its important new IOsorb® plant, IO#7, which began to scale up operations in mid-February and is already contributing significant additional production at more than double the production rate of its predecessor, IO#3. The ramp-up at IO#7 has occurred broadly as expected as Iofina and its brine supply partner continue to work together to maximize brine input and iodine output. As IO#7 optimises its production, the Company expects overall total iodine production rates in Q2 2018 to also increase.

 

Whilst IO#3 has been successfully repurposed to IO#7, a similar determination on the future use of IO#5 is being reviewed. The Company is working with various brine suppliers towards the best utilisation of IO#5, which will either remain at its current location or be relocated to a different site in order to maximise production output while reducing production cost to be a lower quartile producer.

 

Demand for and sales of iodine and iodine based derivatives through Iofina Chemical were as anticipated for the Period. Additionally, Iofina Chemical has added additional chemical reactor capacity for iodide products to meet demands. Prices of iodine and iodine based compounds have risen slightly in the Period continuing their upward trend from 2017.

 

Commenting, President and CEO Dr. Tom Becker, stated: 

''Despite the effects of the weather and brine supply, 2018 iodine production is off to a solid start with the opening of IO#7 midway through the quarter, which is expected to increase output and reduce iodine production costs in Q2 2018. Importantly, commencement of production at IO#7 started on time and management expects output from the plant to increase during the year as it moves to full optimisation. Management continues to review the strategy for IO#5 in order to optimise production from this plant.

 

"The trend of iodine prices continues to move upward and is an additional benefit for Iofina as it moves forward and executes its growth strategy to increase iodine output whilst lowering production costs".

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Emily Morris

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBVVRWWASAAR
Date   Source Headline
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.